How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

PC

NASDAQ:PCVX
Get a brief AI stock analysisSaves ~ 15 minutes of your time

PC

Vaxcyte IncNASDAQ PCVX Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is PCVX undervalued compared to its fair value?

The fair value of PCVX stock is hidden USD. Relative to the market price of 80.09 USD Vaxcyte Inc is hidden.

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 158 full-time employees. The company went IPO on 2020-06-12. The ...[More about valuation]

Vaxcyte Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

9.056 $B

Price:

80.09 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-1.763

FINANCIALS

Vaxcyte financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.12 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.18 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

1.4 B
1.2 B

Financial Position Analysis

Assets

1.4 B
Current Assets
1.1 B
Total non-current assets
0.31 B

Total current liabilities
0.15 B
Total non-current liabilities
0.022 B

Cash Flow Statement

-0.19 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.13 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Vaxcyte fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is PCVX attractive for investment based on fundamental analysis?

PCVX stock rating is hidden. Vaxcyte is a hidden by Eyestock methodology.

Get PCVX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

PCVX analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for PCVX to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Vaxcyte Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Vaxcyte Inc dividends

PCVX dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About PCVX stock

About the company Vaxcyte Inc

Market cap $B

9.056

Dividend yield

Shares outstanding

80.0337 B

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 158 full-time employees. The company went IPO on 2020-06-12. The Company’s pipeline includes pneumococcal conjugate vaccine (PCV), VAX-24, VAX-XP, VAX-A1 and VAX-PG. The Company’s PCV candidates is in development, targeting global pneumococcal vaccine market. The Company’s lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD) and pneumonia. The Company’s PCV candidate, VAX-XP, leverages its scalable and modular platform and builds on the technical proof-of-concept established by VAX-24. VAX-A1 is a novel conjugate vaccine candidate designed to prevent Group A Strep pervasive disease. VAX-PG is a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis and chronic oral inflammatory disease.

PCVX profile

  • Ticker

    PCVX

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    12 June 2020

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    158

  • City

    San Carlos

  • Address

    825 Industrial Road, Ste. 300

  • Cusip

    92243G108